-
15220-10A receptor tyrosine kinase inhibitor that targets VEGF, bFGF, and PDGF&beta receptors, preventing the growth and motility of various cancer cell lines and endothelial cells.
-
15220-25A receptor tyrosine kinase inhibitor that targets VEGF, bFGF, and PDGF&beta receptors, preventing the growth and motility of various cancer cell lines and endothelial cells.
-
15220-5A receptor tyrosine kinase inhibitor that targets VEGF, bFGF, and PDGF&beta receptors, preventing the growth and motility of various cancer cell lines and endothelial cells.
-
15220-50A receptor tyrosine kinase inhibitor that targets VEGF, bFGF, and PDGF&beta receptors, preventing the growth and motility of various cancer cell lines and endothelial cells.
-
18633-1A non-selective &alpha-adrenergic receptor antagonist with pKi values of 8.5, 9, and 8.
-
18633-100A non-selective &alpha-adrenergic receptor antagonist with pKi values of 8.5, 9, and 8.
-
18633-500A non-selective &alpha-adrenergic receptor antagonist with pKi values of 8.5, 9, and 8.
-
15888-1A tricyclic antidepressant that inhibits the reuptake of serotonin and norepinephrine and acts as an antagonist at histamine, serotonin, adrenergic, and muscarinic receptors with Ki values in the nanomolar range.
-
15888-5A tricyclic antidepressant that inhibits the reuptake of serotonin and norepinephrine and acts as an antagonist at histamine, serotonin, adrenergic, and muscarinic receptors with Ki values in the nanomolar range.
-
10253-100An intermediary prodrug of fluorouracil, the pyrimidine analog that inhibits thymidylate synthase selectively in tumor cells, interfering with DNA synthesis one of two intermediary metabolites formed during metabolic conversion of the
-
10253-50An intermediary prodrug of fluorouracil, the pyrimidine analog that inhibits thymidylate synthase selectively in tumor cells, interfering with DNA synthesis one of two intermediary metabolites formed during metabolic conversion of the
-
18746-1A methylxanthine bronchodilator that inhibits phosphodiesterase activity and, thus, increases cAMP demonstrates decreased affinity towards adenosine A1 and A2 receptors, does not interfere with calcium influx into cells, and does not antagonize the